Elke Bestel

2.4k total citations · 2 hit papers
28 papers, 1.7k citations indexed

About

Elke Bestel is a scholar working on Reproductive Medicine, Obstetrics and Gynecology and Genetics. According to data from OpenAlex, Elke Bestel has authored 28 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Reproductive Medicine, 21 papers in Obstetrics and Gynecology and 4 papers in Genetics. Recurrent topics in Elke Bestel's work include Endometriosis Research and Treatment (25 papers), Uterine Myomas and Treatments (21 papers) and Gynecological conditions and treatments (7 papers). Elke Bestel is often cited by papers focused on Endometriosis Research and Treatment (25 papers), Uterine Myomas and Treatments (21 papers) and Gynecological conditions and treatments (7 papers). Elke Bestel collaborates with scholars based in Belgium, Italy and United Kingdom. Elke Bestel's co-authors include Jacques Donnez, Ernest Loumaye, Philippe Bouchard, Ian H. Osterloh, Paul Terrill, Kazem Nouri, Janusz Tomaszewski, Francisco Vega, Т. Ф Татарчук and Olivier Donnez and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Human Reproduction.

In The Last Decade

Elke Bestel

25 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery

2012 478 citations Jacques Donnez, Т. Ф Татарчук et al. New England Journal of Medicine profile →
Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids

2012 415 citations Jacques Donnez, Janusz Tomaszewski et al. New England Journal of Medicine profile →

Peers

Elke Bestel

PHEOH

SURGE

GENET

Paul Terrill Belgium

Maurizio Nicola D’Alterio Italy

Sabina Oldani Italy

Laura L. Holman United States

Sanja Terzic Kazakhstan

Melinda Henne United States

Federica Di Guardo Italy

M. A. Van Eijkeren Netherlands

Daniela Lico Italy

Ibrahim Sozen United States

Paul Terrill Belgium

Elke Bestel

1.1k ×0.7

78 ×0.7

PHEOH

54 ×0.7

SURGE

37 ×0.5

GENET

Citations per year, relative to Elke Bestel Elke Bestel (= 1×) peers Paul Terrill

Countries citing papers authored by Elke Bestel

Since Specialization

Citations

This map shows the geographic impact of Elke Bestel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elke Bestel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elke Bestel more than expected).

Fields of papers citing papers by Elke Bestel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elke Bestel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elke Bestel. The network helps show where Elke Bestel may publish in the future.

Co-authorship network of co-authors of Elke Bestel

This figure shows the co-authorship network connecting the top 25 collaborators of Elke Bestel. A scholar is included among the top collaborators of Elke Bestel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elke Bestel. Elke Bestel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Donnez, Jacques, Felice Petraglia, Hugh S. Taylor, et al.. (2025). Linzagolix with and without hormonal add-back therapy for symptomatic uterine fibroids: PRIMROSE 1 & 2 long-term extension and withdrawal study. Fertility and Sterility. 124(4). 737–748.

Donnez, Jacques, Christian F. W. Becker, Mandy Mangler, et al.. (2025). Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials. Fertility and Sterility. 123(6). 1093–1100. 2 indexed citations

Donnez, Jacques, Christian M. Becker, Hugh S. Taylor, et al.. (2024). Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3). Human Reproduction. 39(6). 1208–1221. 15 indexed citations

Dolmans, Marie‐Madeleine, Andrew W. Horne, Stefan P. Renner, Mitra Boolell, & Elke Bestel. (2024). O-269 Long term efficacy of Linzagolix in women with endometriosis-associated pain. Human Reproduction. 39(Supplement_1).

Dolmans, Marie‐Madeleine, Christian M. Becker, Felice Petraglia, et al.. (2023). O-027 Efficacy results from a phase 3, randomized, placebo-controlled trial testing two doses of linzagolix in women with endometriosis-associated pain. Human Reproduction. 38(Supplement_1).

Donnez, Jacques, Hugh S. Taylor, Elizabeth A. Stewart, et al.. (2022). Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials. The Lancet. 400(10356). 896–907. 39 indexed citations

Donnez, Jacques, Olivier Donnez, Elke Bestel, et al.. (2021). Uterine Adenomyosis Treated by Linzagolix, an Oral Gonadotropin-Releasing Hormone Receptor Antagonist: A Pilot Study with a New ’Hit Hard First and then Maintain’ Regimen of Administration. Journal of Clinical Medicine. 10(24). 5794–5794. 16 indexed citations

Donnez, Jacques, Olivier Donnez, Elke Bestel, et al.. (2021). Treatment of symptomatic uterine adenomyosis with linzagolix, an oral gonadotrophin-releasing hormone antagonist: a pilot study. Reproductive BioMedicine Online. 44(1). 200–203. 12 indexed citations

Donnez, Jacques, Hugh S. Taylor, Robert N. Taylor, et al.. (2020). Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone–antagonist: a randomized clinical trial. Fertility and Sterility. 114(1). 44–55. 79 indexed citations

10.

Stewart, Elizabeth A., Hugh S. Taylor, Robert N. Taylor, et al.. (2020). EFFICACY AND SAFETY OF LINZAGOLIX (LGX) FOR THE TREATMENT OF HEAVY MENSTRUAL BLEEDING (HMB) DUE TO UTERINE FIBROIDS (UF): RESULTS FROM TWO PHASE 3 RANDOMIZED CLINICAL TRIALS. Fertility and Sterility. 114(3). e527–e527. 10 indexed citations

11.

Taylor, Robert N., Elke Bestel, Jean‐Pierre Gotteland, et al.. (2019). Long term treatment of endometriosis associated pain (EAP) with linzagolix: efficacy and safety after 12 months of treatment. Fertility and Sterility. 112(3). e323–e323. 8 indexed citations

12.

Chantraine, Frédéric, et al.. (2015). Expulsion of a uterine myoma in a patient treated with ulipristal acetate. Clinical Case Reports. 3(4). 240–242. 4 indexed citations

13.

Donnez, Jacques, Robert Hudeček, Olivier Donnez, et al.. (2014). Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertility and Sterility. 103(2). 519–527.e3. 144 indexed citations

14.

Donnez, Jacques, Francisco Vega, Janusz Tomaszewski, et al.. (2014). Long-term treatment of uterine fibroids with ulipristal acetate☆. Fertility and Sterility. 101(6). 1565–1573.e18. 245 indexed citations

15.

Barlow, David H., Mary-Ann Lumsden, Bart C.J.M. Fauser, Paul Terrill, & Elke Bestel. (2014). Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo. Human Reproduction. 29(3). 480–489. 18 indexed citations

16.

Pohl, Oliver, Elke Bestel, & Jean‐Pierre Gotteland. (2014). Synergistic Effects of E2MATE and Norethindrone Acetate on Steroid Sulfatase Inhibition: A Randomized Phase I Proof-of-Principle Clinical Study in Women of Reproductive Age. Reproductive Sciences. 21(10). 1256–1265. 21 indexed citations

17.

Donnez, Jacques, Janusz Tomaszewski, Francisco Vega, et al.. (2013). Ulipristal Acetate Versus Leuprolide Acetate for Uterine Fibroids. Obstetrical & Gynecological Survey. 68(2). 99–100. 48 indexed citations

18.

Bestel, Elke & Jacques Donnez. (2013). The potential of selective progesterone receptor modulators for the treatment of uterine fibroids. Expert Review of Endocrinology & Metabolism. 9(1). 79–92. 16 indexed citations

19.

Donnez, Jacques, Т. Ф Татарчук, Philippe Bouchard, et al.. (2012). Ulipristal Acetate versus Placebo for Fibroid Treatment before Surgery. New England Journal of Medicine. 366(5). 409–420. 478 indexed citations breakdown →

20.

Donnez, Jacques, Janusz Tomaszewski, Francisco Vega, et al.. (2012). Ulipristal Acetate versus Leuprolide Acetate for Uterine Fibroids. New England Journal of Medicine. 366(5). 421–432. 415 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact